Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Banka – page 18

231 clinical trials in Banka, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Banka at a glance
231
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

231 trials in Banka

Open in trial search

Study of BAT3306 or pembrolizumab with chemotherapy (carboplatin and pemetrexed) in patients with stage IV non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bio-Thera Solutions Ltd.

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Breast cancer

Not recruiting

Study Comparing ARV-471 and Palbociclib with Letrozole and Palbociclib for Patients with Estrogen Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Erosive oesophagitis

Not recruiting

Study on the Effects and Safety of Pantoprazole for Children and Teens with Healed Erosive Esophagitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years
  • Substances:Pantoprazole Sodium Sesquihydrate
  • Sponsor:Pfizer Inc.

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF

Lung disorder

Not recruiting

Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Oslo University Hospital HF

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Banka

What the registry says about research in the country

01 Neoplasms

In Banka, clinical research is focused on neoplasms, with all active studies centered on breast cancer. The main goal is to better understand how new treatment combinations may improve outcomes for people with hormone-sensitive disease.

  • Advanced/metastatic breast cancer
  • Hormone receptor-positive, HER2-negative breast cancer
  • Testing a new therapy strategy against current treatment options
  • Assessing treatment effectiveness and early tumor response

These studies are exploring whether combining PF-07220060 with standard endocrine treatments can offer better disease control for patients in Slovakia.

02 Breast Cancer Treatment Research

The trials in this city are examining treatment approaches for hormone receptor-positive, HER2-negative breast cancer across both earlier and more advanced disease settings. Research is aimed at refining therapy choices and improving how long cancer stays controlled.

  • Hormone receptor-positive advanced/metastatic breast cancer
  • Neoadjuvant breast cancer treatment
  • Comparing combination therapy with established care
  • Looking at biomarkers such as Ki-67 to understand response

By focusing on both tumor activity and progression control, these studies may help shape more personalized care for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.